Abstract
Objective
To assess the efficacy of intravenous immunoglobulin (IVIG) as add-on treatment for intractable cholangitis (IC) after Kasai portoenterostomy (KPE) in biliary atresia (BA) patients.
Methods
113 BA patients who had one or more episodes of cholangitis after KPE were recruited in this study. According to whether response to routine conservative treatment, all patients were divided into IC group and simple cholangitis (SC) group. Meanwhile, patients with IC subdivided into IVIG group and control group according to whether application of IVIG.
Results
The IC group had higher serum procalcitonin (PCT) (P = 0.014), C-reactive protein (CRP) (P = 0.023), and γ-Gltamyltranspeptidase (γ-GGT) (P = 0.031) level than the SC group. The IVIG group had shorter duration of fever after treatment (P = 0.011) and length of hospital stay (P = 0.018) than the control group. The time until recurrent episode of cholangitis was significant longer in IVIG group than in control group (P = 0.019).
Conclusions
IVIG as add-on treatment may be an effective treatment for the cholangitis acute episode, and we conclude by calling for more prospective studies to attest to the role of IVIG in the treatment of cholangitis.
Similar content being viewed by others
Abbreviations
- BA:
-
Biliary atresia
- KPE:
-
Kasai portoenterostomy
- IVIG:
-
Intravenous immunoglobulin
- IC:
-
Intractable cholangitis
- ALT:
-
Alanine transaminase
- AST:
-
Aspartate transaminase
- SC:
-
Simple cholangitis
- PCT:
-
Procalcitonin
- CRP:
-
C-reactive protein
- γ-GGT:
-
γ-Gltamyltranspeptidase
- WBC:
-
White blood cell count
References
Kasahara M, Umeshita K, Sakamoto S el at (2017) Liver transplantation for biliary atresia: a systematic review. Pediatr Surg Int 33:1289–1295
Bessho K, Bezerra JA (2011) Biliary atresia: will blocking inflammation tame the disease? Annu Rev Med 62:171–185
Hartley JL, Davenport M, Kelly DA (2009) Biliary atresia. Lancet 374:1704–1713
Ecoffey C, Rothman E, Bernard O et al (1987) Bacterial cholangitis after surgery for biliary atresia. J Pediatr 111: 824–829
Wu ET, Chen HL, Ni YH, el at (2001) Bacterial cholangitis in patients with biliary atresia: impact on short-term outcome. Pediatr Surg Int 17:390–395
Ernest VHL, Saing H, Tam PK (2003) Cholangitis after hepatic portoenterostomy for biliary atresia: a multivariate analysis of risk factors. J Pediatr 142:566–571
Liu J, Li G, Lai B (1997) A study on cholangitis after hepatic portoenterostomy for biliary atresia. Chin Med J (Engl) 110:335–337
Ohkohchi N, Chiba T, Ohi R et al (1989) Long-term follow-up study of patients with cholangitis after successful Kasai operation in biliary atresia: selection of recipients for liver transplantation. J Pediatr Gastroenterol Nutr 9:416–420
Davenport M (2017) Adjuvant therapy in biliary atresia: hopelessly optimistic or potential for change? Pediatr Surg Int 33:1263–1273
Gomi H, Solomkin JS, Takada T el at (2013) TG13 antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci 20:60–70
Hureau M, Saint-Leger P (2018) Intravenous immunoglobulin therapy in non-menstrual staphylococcal toxic shock syndrome. Med Mal Infect 48:70–72
Stump SE, Schepers AJ, Jones AR et al (2017) Comparison of weight based dosing strategies for intravenous immunoglobulin in patients with hematologic malignancies. Pharmacotherapy 37:1530–1536
Komori T, Dainichi T, Kusuba N et al (2017) Efficacy of intravenous immunoglobulins for the treatment of mucous membrane pemphigoid-like epidermolysis bullosa acquisita. Eur J Dermatol 27:563–564
Iro MA, Martin NG, Absoud M el at (2017) Intravenous immunoglobulin for the treatment of childhood encephalitis. Cochrane Database Syst Rev 10:D11367
Pourpak Z, Aghamohammadi A, Sedighipour L et al (2006) Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect 39: 114–120
Fenner EK, Boguniewicz J, Tucker RM et al (2014) High-dose IgG therapy mitigates bile duct-targeted inflammation and obstruction in a mouse model of biliary atresia. Pediatr Res 76: 72–80
Lages CS, Simmons J, Chougnet CA et al (2012) Regulatory T cells control the CD8 adaptive immune response at the time of ductal obstruction in experimental biliary atresia. Hepatology 56: 219–227
Okamura A, Harada K, Nio M et al (2013) Participation of natural killer cells in the pathogenesis of bile duct lesions in biliary atresia. J Clin Pathol 66:99–108
Chiang LW, Lee CY, Krishnaswamy G et al (2017) Seventeen years of Kasai portoenterostomy for biliary atresia in a single Southeast Asian paediatric centre. J Paediatr Child Health 53:412–415
Webb NL, Jiwane A, Ooi CY et al (2017) Clinical significance of liver histology on outcomes in biliary atresia. J Paediatr Child Health 53: 252–256
Mones RL, DeFelice AR, Preud’Homme D (1994) Use of neomycin as the prophylaxis against recurrent cholangitis after Kasai portoenterostomy. J Pediatr Surg 29:422–424
Ljungh A, Wadstrom T (2002) The role of microorganisms in biliary tract disease. Curr Gastroenterol Rep 4:167–171
Decharun K, Leys CM, West KW et al (2016) Prophylactic antibiotics for prevention of cholangitis in patients with biliary atresia status post-kasai portoenterostomy: a systematic review. Clin Pediatr (Phila) 55:66–72
Uzzan B, Cohen R, Nicolas P et al (2006) Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 34:1996–2003
Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715–725
Tha-In T, Bayry J, Metselaar HJ et al (2008) Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 29:608–615
Durandy A, Kaveri SV, Kuijpers TW et al (2009) Intravenous immunoglobulins–understanding properties and mechanisms. Clin Exp Immunol 158(Suppl 1):2–13
Esposito S, De Simone G, Boccia G et al (2017) Sepsis and septic shock: new definitions, new diagnostic and therapeutic approaches. J Glob Antimicrob Resist 10: 204–212
Funding
This study was supported by grants from the National Natural Science Foundation of China (no. 81571478).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
The Institutional Review Board of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology approved the protocol of the study (Permit Number 2010-HP0761, Wuhan, China). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Written informed consent was obtained from the guardians of the patients included in this study.
Rights and permissions
About this article
Cite this article
Li, D., Wang, P., He, Y. et al. Intravenous immunoglobulin for the treatment of intractable cholangitis after Kasai portoenterostomy in biliary atresia patients. Pediatr Surg Int 34, 399–404 (2018). https://doi.org/10.1007/s00383-018-4240-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00383-018-4240-6